Daniel b costa (12 Ergebnisse)

Paperback. Zustand: Brand New. 75 pages. 8.94x5.98x0.24 inches. In Stock.

Zustand: As New. Unread book in perfect condition.

162 pp.; 21.5 cm.; sewn bound; duotone; edition size unknown; unsigned and unnumbered; offset-printed; Catalogue of conversations held as part of "Art Basel Conversations," Art Basel Miami Beach, Dec. 2 - 5, 2004 and Art Basel 35, Basel, Switzerland, June 16 - June 21, 2004. Include speakers biographies and directory as well as selected transcripts of conversations. Speakers include John Baldessari, Ute Meta Bauer, Daniel Birnbaum, Stefano Boeri, Paloma Botín, Roger M. Buergel, Janet Cardiff, Catherine David, Lisa Dennison, Trisha Donnelly, Olafur Eliasson, David Elliott, João Fernandes, Antoine de Galbert, Liam Gillick, Zaha Hadid, Kathy Halbreich, Yuko Hasegawa, Hans-Michael Herzog, Marieluise Hessel, Erika Hoffmann, Jens Hoffmann, Jenny Holzer, Kasper König, Rem Koolhaas, Jeff Koons, Gunnar B. Kvaran, Wilfried Lentz, Rosa Martinez, Ivo Costa Mesquita, Paul Morrissey, Ernesto Neto, Hans Ulrich Obrist, Adriano Pedrosa, Anne Philbin, Terence Riley, James Rondeau, Beatrix Ruf, Ricardo Sardenberg, Linda Shearer, Bruce Sterling, Juan Vergez, Mercedes Vilardell, Francesca von Habsburg, Sheena Wagstaff, and Billie Milam Weisman Very Good. Light wear to covers. Contents clean and unmarked. Due to large size and weight additional shipping charges will be required for international orders.…

Taschenbuch. Zustand: Neu. Neuware - Epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) is a clinically important driver alteration affecting approximately one-third of lung cancer patients. Treatments for EGFR-exon 19 deletion and exon 21 L858R NSCLC have evolved over the last decade from first-generation reversible tyrosine kinase inhibitors (TKI) to third-generation irreversible TKIs, of which osimertinib has been the widely accepted as first-line therapy. Despite survival improvement seen with osimertinib and its efficacy against acquired T790M mutation, resistance through on-target and off-target pathways eventually develop. This Element describes the structural biology and pathophysiology of EGFR-mutant NSCLC and discusses past, current, and future treatment options in the metastatic, neoadjuvant, and adjuvant settings. It describes the biology and recently approved treatment for EGFR-exon 20 insertion mutation and the treatment for the uncommon exon 18 (G719X), 20 (S768I), and 21 (L861Q) mutations. It also outlines the promising clinical applications of circulating tumor DNA (ctDNA).…

Kartoniert / Broschiert. Zustand: New. Inhaltsverzeichnis1.Structural biology and mechanism of activation of EGFR 2. EGFR-associated oncogenesis 3. Tyrosine kinase inhibitors (TKIs) as targeted treatment for EGFR-mutant NSCLC 4. EGFR-TKIs as adjuvant or neoadjuvant therapy.

Zustand: New. This is a Brand-new US Edition. This Item may be shipped from US or any other country as we have multiple locations worldwide.

Zustand: New.

Zustand: As New. Unread book in perfect condition.

Zustand: New. In English.

Paperback. Zustand: Brand New. 4th edition. 516 pages. 9.00x7.50x1.25 inches. In Stock.

Zustand: New. Introduces deductive reasoning and helps the reader develop a facility with mathematical proofs Provides a balanced approach to computation and theory by offering computational algorithms for finding eigenvalues and eigenvectors O.

Zustand: New.